Literature DB >> 20736327

Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products.

Soonmo Peter Kang1, Mark J Ratain.   

Abstract

PURPOSE: Several recent oral oncology drugs were labeled for administration in fasted states despite the fact that food increases their bioavailability. Because this was inconsistent with the principles of oral drug delivery, we hypothesized that there were inconsistencies across therapeutic areas. EXPERIMENTAL
DESIGN: Oral agents approved by the U.S. Food and Drug Administration from January 2000 to May 2009 were included in our study. Comparison of the food labeling patterns between oncology and non-oncology drugs was made using Fisher's exact test.
RESULTS: Of the 99 drugs evaluated, 34 showed significant food effects on bioavailability. When food markedly enhanced bioavailability, eight out of nine non-oncology drugs were labeled "fed" to take advantage of the food-drug interaction, whereas all oncology drugs (n = 3) were labeled to be administered in "fasted" states (Fisher's exact test, P = 0.01).
CONCLUSIONS: Drug labeling patterns with respect to food-drug interactions observed with oncology drugs are in contradiction with fundamental pharmacologic principles, as exemplified in the labeling of non-oncology drugs. .

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20736327      PMCID: PMC2932769          DOI: 10.1158/1078-0432.CCR-10-0663

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  25 in total

1.  Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919).

Authors:  H Zhou; S Khalilieh; H Lau; M Guerret; S Osborne; L Alladina; A L Laurent; J F McLeod
Journal:  J Clin Pharmacol       Date:  1999-09       Impact factor: 3.126

Review 2.  Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy.

Authors:  Brahma N Singh; Bimal K Malhotra
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 3.  Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.

Authors:  R J Polinsky
Journal:  Clin Ther       Date:  1998 Jul-Aug       Impact factor: 3.393

4.  The influence of food on the disposition of the antiepileptic rufinamide in healthy volunteers.

Authors:  J M Cardot; J B Lecaillon; C Czendlik; J Godbillon
Journal:  Biopharm Drug Dispos       Date:  1998-05       Impact factor: 1.627

5.  Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies.

Authors:  E T Hellriegel; T D Bjornsson; W W Hauck
Journal:  Clin Pharmacol Ther       Date:  1996-12       Impact factor: 6.875

6.  Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.

Authors:  B Reigner; J Verweij; L Dirix; J Cassidy; C Twelves; D Allman; E Weidekamm; B Roos; L Banken; M Utoh; B Osterwalder
Journal:  Clin Cancer Res       Date:  1998-04       Impact factor: 12.531

Review 7.  Adherence to therapy with oral antineoplastic agents.

Authors:  Ann H Partridge; Jerry Avorn; Philip S Wang; Eric P Winer
Journal:  J Natl Cancer Inst       Date:  2002-05-01       Impact factor: 13.506

8.  Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults.

Authors:  Rachel Courtney; Sudhakar Pai; Mark Laughlin; Josephine Lim; Vijay Batra
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

9.  Effect of food on the pharmacokinetics of multiple-dose oral voriconazole.

Authors:  Lynn Purkins; Nolan Wood; Diane Kleinermans; Katie Greenhalgh; Don Nichols
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

Review 10.  Oral chemotherapy: rationale and future directions.

Authors:  M D DeMario; M J Ratain
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544

View more
  15 in total

Review 1.  United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies.

Authors:  Woondong Jeong; James H Doroshow; Shivaani Kummar
Journal:  Curr Probl Cancer       Date:  2013 May-Jun       Impact factor: 3.187

2.  Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.

Authors:  Ezra E W Cohen; Kehua Wu; Christine Hartford; Masha Kocherginsky; Kimberly Napoli Eaton; Yuanyuan Zha; Anitha Nallari; Michael L Maitland; Kammi Fox-Kay; Kristin Moshier; Larry House; Jacqueline Ramirez; Samir D Undevia; Gini F Fleming; Thomas F Gajewski; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2012-08-07       Impact factor: 12.531

3.  Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer.

Authors:  Shannon E O'Mahar; Toby C Campbell; Tien Hoang; Songwon Seo; KyungMann Kim; Martha M Larson; Sarah M Marcotte; Noelle K LoConte; Anne M Traynor
Journal:  J Thorac Oncol       Date:  2011-05       Impact factor: 15.609

Review 4.  Lipid-associated oral delivery: Mechanisms and analysis of oral absorption enhancement.

Authors:  Oljora Rezhdo; Lauren Speciner; Rebecca Carrier
Journal:  J Control Release       Date:  2016-08-09       Impact factor: 9.776

5.  Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.

Authors:  Mrinal M Gounder; Alona Zer; William D Tap; Samer Salah; Mark A Dickson; Abha A Gupta; Mary Louise Keohan; Herbert H Loong; Sandra P D'Angelo; Stephanie Baker; Mercedes Condy; Kjirsten Nyquist-Schultz; Lanier Tanner; Joseph P Erinjeri; Francis H Jasmine; Sharon Friedlander; Robert Carlson; Thaddeus J Unger; Jean-Richard Saint-Martin; Tami Rashal; Joel Ellis; Michael Kauffman; Sharon Shacham; Gary K Schwartz; Albiruni Ryan Abdul Razak
Journal:  J Clin Oncol       Date:  2016-07-25       Impact factor: 44.544

6.  Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.

Authors:  Manish R Sharma; Theodore G Karrison; Bethany Kell; Kehua Wu; Michelle Turcich; David Geary; Soonmo P Kang; Naoko Takebe; Richard A Graham; Michael L Maitland; Richard L Schilsky; Mark J Ratain; Ezra E W Cohen
Journal:  Clin Cancer Res       Date:  2013-04-03       Impact factor: 12.531

7.  Effects of food and grapefruit juice on single-dose pharmacokinetics of blonanserin in healthy Chinese subjects.

Authors:  De-Wei Shang; Zhan-Zhang Wang; Hai-Tang Hu; Yue-Feng Zhang; Xiao-Jia Ni; Hao-Yang Lu; Ming Zhang; Jin-Qing Hu; Chang Qiu; Huan Peng; Ling-Fang Shen; Yu-Guan Wen
Journal:  Eur J Clin Pharmacol       Date:  2017-10-03       Impact factor: 2.953

8.  Clinical trial simulation to evaluate population pharmacokinetics and food effect: capturing abiraterone and nilotinib exposures.

Authors:  Claire H Li; Eric A Sherer; Lionel D Lewis; Robert R Bies
Journal:  J Clin Pharmacol       Date:  2015-02-04       Impact factor: 3.126

9.  Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.

Authors:  Russell Z Szmulewitz; Cody J Peer; Abiola Ibraheem; Elia Martinez; Mark F Kozloff; Bradley Carthon; R Donald Harvey; Paul Fishkin; Wei Peng Yong; Edmund Chiong; Chadi Nabhan; Theodore Karrison; William D Figg; Walter M Stadler; Mark J Ratain
Journal:  J Clin Oncol       Date:  2018-03-28       Impact factor: 50.717

10.  The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.

Authors:  Jan de Jong; Juthamas Sukbuntherng; Donna Skee; Joe Murphy; Susan O'Brien; John C Byrd; Danelle James; Peter Hellemans; David J Loury; Juhui Jiao; Vijay Chauhan; Erik Mannaert
Journal:  Cancer Chemother Pharmacol       Date:  2015-02-28       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.